CAPTRUST Financial Advisors
LXRX icon

CAPTRUST Financial Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24.1K Buy
15,450
+3,715
+32% +$5.4K ﹤0.01% 2951
2025
Q4 		$13.5K Sell
11,735
-2,334
-17% -$3.21K ﹤0.01% 2727
2025
Q3 		$19K Sell
14,069
-21,513
-60% -$24.4K ﹤0.01% 2607
2025
Q2 		$33.6K Buy
35,582
+2,398
+7% +$1.55K ﹤0.01% 2457
2025
Q1 		$15.3K Buy
33,184
+19,826
+148% +$12.5K ﹤0.01% 2329
2024
Q4 		$9.87K Buy
13,358
+2,008
+18% +$2.42K ﹤0.01% 2280
2024
Q3 		$17.8K Buy
11,350
+485
+4% +$864 ﹤0.01% 2262
2024
Q2 		$18.3K Buy
10,865
+54
+0.5% +$97 ﹤0.01% 2175
2024
Q1 		$25.9K Sell
10,811
-33,825
-76% -$72.7K ﹤0.01% 2108
2023
Q4 		$68.3K Buy
44,636
+18
+0% +$21 ﹤0.01% 2562
2023
Q3 		$48.6K Sell
44,618
-1,871
-4% -$3.28K ﹤0.01% 2481
2023
Q2 		$106K Hold
46,489
– – ﹤0.01% 2369
2023
Q1 		$113K Buy
+46,489
New +$107K ﹤0.01% 2142
2022
Q1 		– Sell
-1
Closed – – 5044
2021
Q4 		$0 Buy
+1
New +$5 ﹤0.01% 4848
2021
Q3 		– Sell
-1
Closed – – 4713
2021
Q2 		$0 Hold
1
– – ﹤0.01% 4595
2021
Q1 		$0 Buy
+1
New +$7 ﹤0.01% 4427

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

CAPTRUST Financial Advisors's LXRX Position: Q1 2026 in Review

CAPTRUST Financial Advisors increased its Lexicon Pharmaceuticals (LXRX) stake by 32% in Q1 2026, buying an estimated $5.4K and bringing the position to 15,450 shares worth $24.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2951.

CAPTRUST Financial Advisors first reported a position in LXRX in Q1 2021 and has held it in 16 quarters since. The position peaked at $113K in Q1 2023. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.

  • CAPTRUST Financial Advisors held 15,450 shares of Lexicon Pharmaceuticals worth $24.1K as of Q1 2026.
  • CAPTRUST Financial Advisors bought 3,715 Lexicon Pharmaceuticals shares in Q1 2026, an estimated $5.4K.
  • Lexicon Pharmaceuticals made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q1 2026, its #2951 holding.
  • CAPTRUST Financial Advisors first reported a position in Lexicon Pharmaceuticals in Q1 2021 and has held it in 16 quarters since.
  • CAPTRUST Financial Advisors's Lexicon Pharmaceuticals position peaked at $113K in Q1 2023.
  • 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q1 2026, filed 15 May 2026.